Onclara™ (by Onc.ai)
Overview
Onc.ai is a digital health company dedicated to radically improving oncology decision-making through advanced AI. Their flagship Onclara™ platform leverages a market-leading real-world oncology dataset to train best-in-class predictive and prognostic AI models. This technology aims to provide physicians and pharmaceutical companies with deeper insights for more effective cancer treatment strategies and clinical trial management.
The Onclara™ platform offers two primary products: Onclara™ Evaluate and Onclara™ IO. Onclara™ Evaluate is designed to enhance Phase IB/Phase II clinical trial decision-making for pharmaceutical companies, having received FDA Breakthrough Device Designation. This product helps optimize trial design and patient selection, potentially accelerating the development of new cancer therapies.
Onclara™ IO focuses on clinical practice, specifically predicting response and outcomes for patients with metastatic lung cancer treated with immunotherapy. By providing prognostic insights, Onclara™ IO can assist physicians in personalizing treatment plans and managing patient expectations more effectively. The platform’s models are continuously validated against comprehensive real-world datasets, ensuring their relevance and accuracy in a clinical setting.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered predictive and prognostic models
- Leverages real-world oncology datasets
- Improves Phase IB/Phase II clinical trial decision-making
- Predicts response and outcomes for metastatic lung cancer with immunotherapy
- Imaging AI for oncology
- Serial Imaging Response Score (SIRS)
- Validated on comprehensive real-world datasets (e.g., Flatiron Health)
Use Cases
- Optimizing oncology clinical trial design and patient selection
- Predicting immunotherapy response in metastatic lung cancer
- Personalizing cancer treatment plans
- Early assessment of NSCLC immunotherapy outcomes
- Enhancing clinical decision-making in oncology
What Physicians Need to Know
Onclarau2122 offers AI-powered insights for oncology, particularly in predicting treatment response and outcomes for metastatic lung cancer and improving clinical trial decision-making. Physicians should note its FDA Breakthrough Device Designation for Onclarau2122 Evaluate. The platform aims to provide actionable reports from routine CT scans, potentially aiding in patient stratification and treatment selection. While designed for seamless integration, understanding the AI model's specific outputs (e.g., risk stratification for overall survival) and how they complement traditional assessments like PD-L1 testing is crucial for optimal utilization.
Onclarau2122 can be deployed directly in pharma cloud environments (e.g., Microsoft Azure Foundry) or utilize secure upload to Onclarau2122 Studio (cloud-hosted). It supports data transfer with leading pharma/oncology CROs and is designed to integrate with oncology EMRs for returning predictions. The system handles CT scans from all major hardware vendors and harmonizes them for analysis.
Details
| Category | Clinical Decision Support & Reference, Oncology AI, Radiology & Imaging AI |
| Pricing | Unknown — unknown |
| Deployment | Cloud-hosted (Onclara™ Studio, Microsoft Azure Foundry) |
| Mobile App | OncoCare (by Onco AI) is available on the Apple App Store, but it is unclear if this is directly related to Onc.ai's Onclara™ platform. |
| API Available | Unknown |
| Data Export | Unknown |
| Languages | English |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated Onclara™ Evaluate is FDA-breakthrough designated. Onclara™ IO is not yet FDA cleared and is not available for commercial use, but Onc.AI expects to submit Onclara IO for clearance as a software-as-medical-device in 2027. The Serial CT Response Score (Serial CTRS) AI model received FDA Breakthrough Device Designation in February 2025. |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Pulmonology, Radiology |
Social Proof
| Customers | unknown |
| Notable | Flatiron HealthGSKPfizer (for clinical trial validations) |
What the Web Says
Onclarau2122 by Onc.ai is an AI-powered platform designed to improve oncology decision-making by leveraging real-world oncology datasets to train predictive and prognostic AI models. Its products, Onclarau2122 Evaluate and Onclarau2122 IO, aim to enhance clinical trial decision-making for pharmaceutical companies and predict treatment response and outcomes for metastatic lung cancer patients receiving immunotherapy. The platform has received FDA Breakthrough Device Designation for Onclarau2122 Evaluate and is undergoing rigorous external validation.
Overall: PositiveStrengths
- Improves Phase IB/Phase II clinical trial decision-making for pharmaceutical companies.
- Predicts response and outcomes for metastatic lung cancer patients treated with immunotherapy.
- Leverages a market-leading oncology real-world dataset to train AI models.
- Onclarau2122 Evaluate has FDA Breakthrough Device Designation.
- Provides comprehensive and intuitive reports to oncologists within 24 hours.
- Validated on comprehensive metastatic real-world datasets and clinical trials.
Limitations
- Onclarau2122 IO is not yet FDA cleared and is not available for commercial use, with submission expected in 2027.
- General concerns about AI in oncology include the potential for hallucinations, liability, ethics, and the irreplaceable value of human interaction.
- Some Reddit discussions indicate a general skepticism about AI replacing the nuanced critical thinking and patient interaction of oncologists.
- Limited independent physician or tech reviewer opinions specifically on Onclarau2122 were found outside of company announcements and scientific validations.
Based on reviews from: Onc.ai, Business Wire, Reddit, OncLive
Last updated: 2026-06-19
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Onclara™ (by Onc.ai)
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Onclara™ (by Onc.ai).
No videos found. Search YouTube directly
Frequently Asked Questions
Compare Onclara™ (by Onc.ai)
VS
VS
VS
VS
Investors who backed Onclara™ (by Onc.ai)
Funded through the company that built this tool.
